Recent Quotes (30 days)

You have no recent quotes
chg | %

Shire PLC news

   Watch this stock
Showing stories 1 - 10 of about 110   

Articles published

SHP 4,925.51 +109.51 (2.27%)
price chart
Why I'm Selling GlaxoSmithKline plc And Buying Shire PLC
Finding a company that has the perfect blend of both growth and income is a difficult game to play. However, it looks as if Shire (LSE: SHP) could be the perfect pick. Up until now, my pharmaceutical sector favourite has been GlaxoSmithKline (LSE: GSK ...
3 Fast-Growing Pharmaceuticals Set To Outperform: Shire PLC, BTG plc and ...
Back in February last year I penned an article titled David & Goliath: AstraZeneca versus Hikma Pharmaceuticals, which compared the prospects of the two firms and suggested that looking down the food chain in the pharmaceutical sector could produce an ...
Shire plc (SHPG) Comments on FDA Approval of NATPARA (NPSP)
Shire plc (Nasdaq: SHPG) notes the announcement by NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) that the U.S. Food and Drug Administration (FDA) has approved NATPARA (parathyroid hormone) as an adjunct to calcium and vitamin D to control ...
FDA approves NPS drug, in move validating Shire takeover deal  Reuters
Shire shares jump as drug approval vindicates $5.2 billion NPS purchase  Yahoo News UK
How Will GlaxoSmithKline plc, AstraZeneca plc And Shire PLC Fare During 2015?
You don't need me to tell you that safety-conscious, conservative investors with a penchant for defensive shares endured something of a sustained pummelling during 2014 from that traditional safe haven, the supermarket sector.
Related articles »  
Shire plc (SHPG) Receives FDA Fast-Track Designation for SHP609
Shire plc (NASDAQ: SHPG) announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation for SHP609 (idursulfase-IT; also known as HGT-2310) for the treatment of neurocognitive decline associated with Hunter ...
Shire' SHP609 Gets Fast Track Status From FDA - Quick Facts  RTT News
Why I Think Shire plc Will Outperform AstraZeneca plc And GlaxoSmithKline plc ...
You probably know everything about GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) by now: a bribery scandal in China, falling earnings and a patent cliff have all weighed on its equity valuation in recent times.
Shire PLC Rating Reiterated by Kepler Capital Markets (SHP)
Shire PLC logo Shire PLC (LON:SHP)'s stock had its �buy� rating reaffirmed by equities researchers at Kepler Capital Markets in a research report issued on Friday.
Shire PLC Rating Reiterated by Shore Capital (SHP)  sleekmoney
Vodafone Group plc's "Hold" Rating Reaffirmed at Jefferies ...  Ticker Report
AstraZeneca plc, GlaxoSmithKline plc And Shire PLC Are Set For A Decade Of ...
The UK three main pharmaceutical companies, AstraZeneca (LSE: AZN), GlaxoSmithKline (LSE: GSK) and Shire (LSE: SHP) are all at key stages in the development of their treatment pipelines.
Is it Time to Buy Shire? (NASDAQ:SHPG)
[PRNewsWire]Shire PLC (ADR) (NASDAQ:SHPG) announces the positive response from the European Decentralised Procedure (DCP) for Elvanse Adult� in the three European countries participating in the procedure (UK, Denmark and Sweden).
Shire PLC Given New $248.00 Price Target at RBC Capital (SHPG)
Shire PLC logo Stock analysts at RBC Capital increased their price objective on shares of Shire PLC (NASDAQ:SHPG) from $238.00 to $248.00 in a report issued on Monday.